{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T02:29:35Z","timestamp":1793672975531,"version":"4.5.1"},"reference-count":134,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100012678","name":"Young Teacher Foundation of Sun Yat-sen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012678","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018610","name":"Innovation Program in Military Medicine of Chinese People\u2019s Liberation Army","doi-asserted-by":"publisher","award":["ZY2023F149"],"award-info":[{"award-number":["ZY2023F149"]}],"id":[{"id":"10.13039\/501100018610","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.bcp.2024.116471","type":"journal-article","created":{"date-parts":[[2024,8,8]],"date-time":"2024-08-08T13:10:51Z","timestamp":1723122651000},"page":"116471","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"special_numbering":"C","title":["Peptide GLP-1 receptor agonists: From injection to oral delivery strategies"],"prefix":"10.1016","volume":"229","author":[{"given":"Zhiqiang","family":"Ke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaonan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanlin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyuan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhengding","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2024.116471_b0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/s42255-020-00327-x","article-title":"Metabolic Messengers: glucagon-like peptide 1","volume":"3","author":"Gribble","year":"2021","journal-title":"Nat. Metab."},{"issue":"7657","key":"10.1016\/j.bcp.2024.116471_b0010","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/nature22394","article-title":"Cryo-EM structure of the activated GLP-1 receptor in complex with a G protein","volume":"546","author":"Zhang","year":"2017","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.bcp.2024.116471_b0015","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.molcel.2020.09.020","article-title":"Differential GLP-1R binding and activation by peptide and non-peptide agonists","volume":"80","author":"Zhang","year":"2020","journal-title":"Mol. Cell"},{"key":"10.1016\/j.bcp.2024.116471_b0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.molmet.2020.101102","article-title":"GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art","volume":"46","author":"Nauck","year":"2021","journal-title":"Mol. Metab."},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0025","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/j.nefroe.2023.09.003","article-title":"Glucagon-like peptide 1(GLP-1) receptor agonists in the management of the patient with type 2diabetes mellitus and chronic kidney disease: an approach for the nephrologist","volume":"43","author":"Cases","year":"2023","journal-title":"Nefrologia (Engl. Ed)"},{"key":"10.1016\/j.bcp.2024.116471_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2022.175439","article-title":"Alternative role of glucagon-like Peptide-1 receptor agonists in neurodegenerative diseases","volume":"938","author":"Chen","year":"2023","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0035","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s11154-023-09807-3","article-title":"Effects of GLP-1 receptor agonists on neurological complications of diabetes","volume":"24","author":"Garcia-Casares","year":"2023","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"6676","key":"10.1016\/j.bcp.2024.116471_b0040","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1126\/science.adn4691","article-title":"Obesity meets its match","volume":"382","author":"Couzin-Frankel","year":"2023","journal-title":"Science"},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0045","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1111\/bph.15647","article-title":"Glucagon-like peptide-1 in diabetes care: can glycaemic control be achieved without nausea and vomiting?","volume":"179","author":"Borner","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116471_b0050","doi-asserted-by":"crossref","first-page":"1043789","DOI":"10.3389\/fendo.2022.1043789","article-title":"Association between different GLP-1 receptor agonists and gastrointestinal adverse reactions: a real-world disproportionality study based on FDA adverse event reporting system database","volume":"13","author":"Liu","year":"2022","journal-title":"Front. Endocrinol. (Lausanne)"},{"issue":"10","key":"10.1016\/j.bcp.2024.116471_b0055","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1111\/dom.14089","article-title":"A second-generation glucagon-like peptide-1 receptor agonist mitigates vomiting and anorexia while retaining glucoregulatory potency in lean diabetic and emetic mammalian models","volume":"22","author":"Borner","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"10","key":"10.1016\/j.bcp.2024.116471_b0060","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1007\/s40262-013-0079-0","article-title":"Pharmacokinetics and pharmacokinetic-pharmacodynamic correlations of therapeutic peptides","volume":"52","author":"Diao","year":"2013","journal-title":"Clin. Pharmacokinet."},{"issue":"6","key":"10.1016\/j.bcp.2024.116471_b0065","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14656566.2017.1282463","article-title":"Exenatide: pharmacokinetics, clinical use, and future directions","volume":"18","author":"Knop","year":"2017","journal-title":"Expert Opin. Pharmacother."},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0070","first-page":"214","article-title":"Bydureon: first once weekly GLP-1 receptor agonist (exenatide LAR)","volume":"69","author":"Scheen","year":"2014","journal-title":"Rev. Med. Liege"},{"issue":"9","key":"10.1016\/j.bcp.2024.116471_b0075","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1358\/dot.2013.49.09.2020940","article-title":"Lixisenatide for the treatment of type 2 diabetes","volume":"49","author":"Petersen","year":"2013","journal-title":"Drugs Today (Barc)"},{"issue":"8","key":"10.1016\/j.bcp.2024.116471_b0080","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1002\/phar.1962","article-title":"Lixisenatide, a once-daily prandial glucagon-like peptide-1 receptor agonist for the treatment of adults with type 2 diabetes","volume":"37","author":"Trujillo","year":"2017","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.bcp.2024.116471_b0085","doi-asserted-by":"crossref","first-page":"2714","DOI":"10.1111\/bcp.14091","article-title":"Polyethylene glycol loxenatide (PEX168) in subjects with renal impairment: a pharmacokinetic study","volume":"85","author":"Wang","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0090","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s13300-022-01336-7","article-title":"Long-term cost-effectiveness of subcutaneous once-weekly semaglutide versus polyethylene glycol loxenatide for treatment of type 2 diabetes mellitus in china","volume":"14","author":"Liu","year":"2023","journal-title":"Diabetes Ther."},{"issue":"12","key":"10.1016\/j.bcp.2024.116471_b0095","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1111\/dom.14163","article-title":"Efficacy and safety of polyethylene glycol loxenatide as add-on to metformin in patients with type 2 diabetes: a multicentre, randomized, double-blind, placebo-controlled, phase 3b trial","volume":"22","author":"Gao","year":"2020","journal-title":"Diabetes Obes. Metab."},{"issue":"13","key":"10.1016\/j.bcp.2024.116471_b0100","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCULATIONAHA.122.063716","article-title":"Exploring the relationship between efpeglenatide dose and cardiovascular outcomes in type 2 diabetes: insights from the AMPLITUDE-O Trial","volume":"147","author":"Gerstein","year":"2023","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.bcp.2024.116471_b0105","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.2337\/dc18-2648","article-title":"Once-weekly efpeglenatide dose-range effects on glycemic control and body weight in patients with type 2 diabetes on metformin or drug na\u00efve, referenced to liraglutide","volume":"42","author":"Rosenstock","year":"2019","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0110","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/s41591-021-01584-3","article-title":"Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial","volume":"28","author":"Ruff","year":"2022","journal-title":"Nat. Med."},{"issue":"22","key":"10.1016\/j.bcp.2024.116471_b0115","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1056\/NEJMoa1916038","article-title":"Controlled trial of liraglutide for adolescents with obesity","volume":"382","author":"Kelly","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.bcp.2024.116471_b0120","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.2147\/DDDT.S58459","article-title":"Liraglutide and obesity: a review of the data so far","volume":"9","author":"Ladenheim","year":"2015","journal-title":"Drug Des. Devel. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2024.116471_b0125","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1517\/17425255.2015.1068288","article-title":"Albiglutide for treating type 2 diabetes: an evaluation of pharmacokinetics\/pharmacodynamics and clinical efficacy","volume":"11","author":"Bronden","year":"2015","journal-title":"Expert Opin. Drug Metab. Toxicol."},{"key":"10.1016\/j.bcp.2024.116471_b0130","unstructured":"A.F. Hernandez, J.B. Green, S. Janmohamed, R.B. D'Agostino, Sr., C.B. Granger, N.P. Jones, L.A. Leiter, A.E. Rosenberg, K.N. Sigmon, M.C. Somerville, K.M. Thorpe, J.J.V. McMurray, S. Del Prato, c. Harmony Outcomes, investigators, Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial, Lancet 392(10157) (2018) 1519-1529."},{"issue":"5","key":"10.1016\/j.bcp.2024.116471_b0135","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1056\/NEJMoa2204601","article-title":"Once-weekly dulaglutide for the treatment of youths with type 2 diabetes","volume":"387","author":"Arslanian","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2024.116471_b0140","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1002\/dmrr.2810","article-title":"Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program","volume":"32","author":"Jendle","year":"2016","journal-title":"Diabetes Metab. Res. Rev."},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0145","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1002\/osp4.342","article-title":"Beinaglutide showed significant weight-loss benefit and effective glycaemic control for the treatment of type 2 diabetes in a real-world setting: a 3-month, multicentre, observational, retrospective, open-label study","volume":"5","author":"Zhang","year":"2019","journal-title":"Obes. Sci. Pract."},{"issue":"10192","key":"10.1016\/j.bcp.2024.116471_b0150","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(19)31271-1","article-title":"Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial","volume":"394","author":"Pratley","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2024.116471_b0155","doi-asserted-by":"crossref","unstructured":"J.P.H. Wilding, R.L. Batterham, S. Calanna, M. Davies, L.F. Van Gaal, I. Lingvay, B.M. McGowan, J. Rosenstock, M.T.D. Tran, T.A. Wadden, S. Wharton, K. Yokote, N. Zeuthen, R.F. Kushner, S.S. Group, Once-Weekly Semaglutide in Adults with Overweight or Obesity, N Engl J Med 384(11) (2021) 989-1002.","DOI":"10.1056\/NEJMoa2032183"},{"issue":"2","key":"10.1016\/j.bcp.2024.116471_b0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109374","article-title":"Structure and dynamics of semaglutide- and taspoglutide-bound GLP-1R-Gs complexes","volume":"36","author":"Zhang","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0165","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1208\/s12248-012-9441-7","article-title":"In vitro and in vivo evaluation of a water-in-oil microemulsion system for enhanced peptide intestinal delivery","volume":"15","author":"Liu","year":"2013","journal-title":"AAPS J."},{"issue":"9","key":"10.1016\/j.bcp.2024.116471_b0170","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s40265-021-01499-w","article-title":"A pharmacological and clinical overview of oral semaglutide for the treatment of type 2 diabetes","volume":"81","author":"Andersen","year":"2021","journal-title":"Drugs"},{"issue":"10","key":"10.1016\/j.bcp.2024.116471_b0175","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1056\/NEJMoa2302392","article-title":"Daily oral GLP-1 receptor agonist orforglipron for adults with obesity","volume":"389","author":"Wharton","year":"2023","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.bcp.2024.116471_b0180","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1016\/j.apsb.2021.04.001","article-title":"Oral delivery of proteins and peptides: challenges, status quo and future perspectives","volume":"11","author":"Zhu","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0185","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41392-022-00904-4","article-title":"Therapeutic peptides: current applications and future directions","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.bcp.2024.116471_b0190","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1021\/acs.bioconjchem.3c00120","article-title":"Glycosylation improves the proteolytic stability of exenatide","volume":"34","author":"Chandrashekar","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bcp.2024.116471_b0195","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171003","article-title":"The molecular pharmacology of glucagon agonists in diabetes and obesity","volume":"165","author":"Novikoff","year":"2023","journal-title":"Peptides"},{"issue":"2","key":"10.1016\/j.bcp.2024.116471_b0200","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1021\/bc049735+","article-title":"Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1","volume":"16","author":"Lee","year":"2005","journal-title":"Bioconjug. Chem."},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0205","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1021\/bc100404x","article-title":"Mono-PEGylated dimeric exendin-4 as high receptor binding and long-acting conjugates for type 2 anti-diabetes therapeutics","volume":"22","author":"Kim","year":"2011","journal-title":"Bioconjug. Chem."},{"key":"10.1016\/j.bcp.2024.116471_b0210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114672","article-title":"Site-specific N-terminal PEGylation-based controlled release of biotherapeutics: an application for GLP-1 delivery to improve pharmacokinetics and prolong hypoglycemic effects","volume":"242","author":"Lin","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116471_b0215","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.jconrel.2018.05.001","article-title":"PEGylated prodrugs of antidiabetic peptides amylin and GLP-1","volume":"292","author":"Bottger","year":"2018","journal-title":"J. Control. Release"},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0220","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2020868118","article-title":"Oral administration of PEGylated TLR7 ligand ameliorates alcohol-associated liver disease via the induction of IL-22","volume":"118","author":"Wang","year":"2021","journal-title":"PNAS"},{"issue":"47","key":"10.1016\/j.bcp.2024.116471_b0225","doi-asserted-by":"crossref","first-page":"11184","DOI":"10.1039\/D3TB02207B","article-title":"A review of recent research and development on GLP-1 receptor agonists-sustained-release microspheres","volume":"11","author":"Gao","year":"2023","journal-title":"J. Mater. Chem. B"},{"issue":"8","key":"10.1016\/j.bcp.2024.116471_b0230","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1021\/acschembio.7b00218","article-title":"A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist","volume":"12","author":"Schneider","year":"2017","journal-title":"ACS Chem. Biol."},{"issue":"11","key":"10.1016\/j.bcp.2024.116471_b0235","doi-asserted-by":"crossref","first-page":"3356","DOI":"10.1111\/dom.15235","article-title":"Development of a novel Fc fusion protein dual glucagon-like peptide-1 and gastric inhibitory polypeptide receptor agonists","volume":"25","author":"Jiang","year":"2023","journal-title":"Diabetes Obes. Metab."},{"key":"10.1016\/j.bcp.2024.116471_b0240","doi-asserted-by":"crossref","first-page":"343","DOI":"10.2147\/DMSO.S421527","article-title":"Research advances in fusion protein-based drugs for diabetes treatment","volume":"17","author":"Deng","year":"2024","journal-title":"Diabetes Metab. Syndr. Obes."},{"issue":"29","key":"10.1016\/j.bcp.2024.116471_b0245","doi-asserted-by":"crossref","first-page":"4930","DOI":"10.1002\/anie.201000287","article-title":"A protease-based strategy for the controlled release of therapeutic peptides","volume":"49","author":"Li","year":"2010","journal-title":"Angew. Chem. Int. Ed. Engl."},{"issue":"Pt B","key":"10.1016\/j.bcp.2024.116471_b0250","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.addr.2016.06.005","article-title":"Intestinal permeation enhancers for oral peptide delivery","volume":"106","author":"Maher","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.bcp.2024.116471_b0255","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s11154-022-09735-8","article-title":"A new era for oral peptides: SNAC and the development of oral semaglutide for the treatment of type 2 diabetes","volume":"23","author":"Aroda","year":"2022","journal-title":"Rev. Endocr. Metab. Disord."},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0260","doi-asserted-by":"crossref","first-page":"74","DOI":"10.2337\/cd22-0118","article-title":"Current understanding of sodium N-(8-[2-hydroxylbenzoyl] amino) caprylate (SNAC) as an absorption enhancer: the oral semaglutide experience","volume":"42","author":"Solis-Herrera","year":"2024","journal-title":"Clin Diabetes"},{"key":"10.1016\/j.bcp.2024.116471_b0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.carbpol.2020.116594","article-title":"Chitosan: a promising therapeutic agent and effective drug delivery system in managing diabetes mellitus","volume":"247","author":"Sarkar","year":"2020","journal-title":"Carbohydr. Polym."},{"issue":"5","key":"10.1016\/j.bcp.2024.116471_b0270","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1166\/jbn.2015.1971","article-title":"Exendin-4 loaded nanoparticles with a lipid shell and aqueous core containing micelles for enhanced intestinal absorption","volume":"11","author":"Chen","year":"2015","journal-title":"J. Biomed. Nanotechnol."},{"issue":"11","key":"10.1016\/j.bcp.2024.116471_b0275","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics11110599","article-title":"Encapsulation in polymeric nanoparticles enhances the enzymatic stability and the permeability of the GLP-1 analog, liraglutide, across a culture model of intestinal permeability","volume":"11","author":"Ismail","year":"2019","journal-title":"Pharmaceutics"},{"issue":"32","key":"10.1016\/j.bcp.2024.116471_b0280","doi-asserted-by":"crossref","first-page":"e2102044","DOI":"10.1002\/adma.202102044","article-title":"A pH-triggered self-unpacking capsule containing zwitterionic hydrogel-coated MOF nanoparticles for efficient oral exendin-4 delivery","volume":"33","author":"Zhou","year":"2021","journal-title":"Adv. Mater."},{"issue":"33","key":"10.1016\/j.bcp.2024.116471_b0285","doi-asserted-by":"crossref","first-page":"29593","DOI":"10.1021\/acsami.9b10294","article-title":"Surface coating approach to overcome mucosal entrapment of DNA nanoparticles for oral gene delivery of glucagon-like peptide 1","volume":"11","author":"Nie","year":"2019","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0290","doi-asserted-by":"crossref","first-page":"e86064","DOI":"10.1371\/journal.pone.0086064","article-title":"Oral delivery of exenatide via microspheres prepared by cross-linking of alginate and hyaluronate","volume":"9","author":"Zhang","year":"2014","journal-title":"PLoS One"},{"issue":"7","key":"10.1016\/j.bcp.2024.116471_b0295","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1021\/acs.molpharmaceut.8b00344","article-title":"Long-acting release microspheres containing novel GLP-1 analog as an antidiabetic system","volume":"15","author":"Ruan","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.bcp.2024.116471_b0300","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.114076","article-title":"Clinical translation of advanced colonic drug delivery technologies","volume":"181","author":"Awad","year":"2022","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"19","key":"10.1016\/j.bcp.2024.116471_b0305","doi-asserted-by":"crossref","first-page":"e2200192","DOI":"10.1002\/mnfr.202200192","article-title":"Colonic delivery of nutrients for sustained and prolonged release of gut peptides: a novel strategy for appetite management","volume":"66","author":"Kamakura","year":"2022","journal-title":"Mol. Nutr. Food Res."},{"issue":"10","key":"10.1016\/j.bcp.2024.116471_b0310","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1016\/j.biomaterials.2010.12.044","article-title":"The glucose-lowering potential of exendin-4 orally delivered via a pH-sensitive nanoparticle vehicle and effects on subsequent insulin secretion in vivo","volume":"32","author":"Nguyen","year":"2011","journal-title":"Biomaterials"},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0315","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1517\/17425247.2011.539200","article-title":"Vitamin B12 in drug delivery: breaking through the barriers to a B12 bioconjugate pharmaceutical","volume":"8","author":"Clardy","year":"2011","journal-title":"Expert Opin. Drug Deliv."},{"issue":"9","key":"10.1016\/j.bcp.2024.116471_b0320","doi-asserted-by":"crossref","first-page":"3502","DOI":"10.1021\/acs.molpharmaceut.5b00390","article-title":"Enhanced peptide stability against protease digestion induced by intrinsic factor binding of a vitamin B12 conjugate of exendin-4","volume":"12","author":"Bonaccorso","year":"2015","journal-title":"Mol. Pharm."},{"issue":"6","key":"10.1016\/j.bcp.2024.116471_b0325","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.1021\/acs.jmedchem.1c00185","article-title":"Synthesis, optimization, and biological evaluation of corrinated conjugates of the GLP-1R agonist exendin-4","volume":"64","author":"Tinsley","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116471_b0330","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2023.171134","article-title":"Corrination mitigates peptide aggregation as exemplified for Glucagon","volume":"171","author":"Liles","year":"2024","journal-title":"Peptides"},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0335","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/cmdc.201200461","article-title":"Synthesis, characterization and pharmacodynamics of vitamin-B(12)-conjugated glucagon-like peptide-1","volume":"8","author":"Clardy-James","year":"2013","journal-title":"ChemMedChem"},{"issue":"5","key":"10.1016\/j.bcp.2024.116471_b0340","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1111\/dom.13222","article-title":"A vitamin B12 conjugate of exendin-4 improves glucose tolerance without associated nausea or hypophagia in rodents","volume":"20","author":"Mietlicki-Baase","year":"2018","journal-title":"Diabetes Obes. Metab."},{"issue":"11","key":"10.1016\/j.bcp.2024.116471_b0345","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2020.107768","article-title":"Corrination of a GLP-1 receptor agonist for glycemic control without emesis","volume":"31","author":"Borner","year":"2020","journal-title":"Cell Rep."},{"issue":"7","key":"10.1016\/j.bcp.2024.116471_b0350","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics13070987","article-title":"Cell-penetrating peptides and transportan","volume":"13","author":"Langel","year":"2021","journal-title":"Pharmaceutics"},{"issue":"2","key":"10.1016\/j.bcp.2024.116471_b0355","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1073\/pnas.91.2.664","article-title":"Tat-mediated delivery of heterologous proteins into cells","volume":"91","author":"Fawell","year":"1994","journal-title":"PNAS"},{"issue":"3","key":"10.1016\/j.bcp.2024.116471_b0360","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12030225","article-title":"Cell penetrating peptides, novel vectors for gene therapy","volume":"12","author":"Taylor","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2024.116471_b0365","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.69832","article-title":"Genetic, cellular, and structural characterization of the membrane potential-dependent cell-penetrating peptide translocation pore","volume":"10","author":"Trofimenko","year":"2021","journal-title":"Elife"},{"issue":"5","key":"10.1016\/j.bcp.2024.116471_b0370","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14050907","article-title":"Redesigning of cell-penetrating peptides to improve their efficacy as a drug delivery system","volume":"14","author":"Szabo","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.bcp.2024.116471_b0375","article-title":"Coating of PLA-nanoparticles with cyclic, arginine-rich cell penetrating peptides enables oral delivery of liraglutide","volume":"24","author":"Uhl","year":"2020","journal-title":"Nanomedicine"},{"issue":"6657","key":"10.1016\/j.bcp.2024.116471_b0380","doi-asserted-by":"crossref","first-page":"eadd5787","DOI":"10.1126\/science.add5787","article-title":"Microbial-host-isozyme analyses reveal microbial DPP4 as a potential antidiabetic target","volume":"381","author":"Wang","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0385","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12938-022-01046-y","article-title":"Comprehensive bibliometric and visualized analysis of research on fecal microbial transplantation published from 2000 to 2021","volume":"21","author":"Ma","year":"2022","journal-title":"Biomed. Eng. Online"},{"issue":"2","key":"10.1016\/j.bcp.2024.116471_b0390","doi-asserted-by":"crossref","first-page":"2274124","DOI":"10.1080\/19490976.2023.2274124","article-title":"Gut microbiota regulates postprandial GLP-1 response via ileal bile acid-TGR5 signaling","volume":"15","author":"Wang","year":"2023","journal-title":"Gut Microbes"},{"issue":"23","key":"10.1016\/j.bcp.2024.116471_b0395","doi-asserted-by":"crossref","first-page":"7437","DOI":"10.1128\/AEM.01019-08","article-title":"Secretion of insulinotropic proteins by commensal bacteria: rewiring the gut to treat diabetes","volume":"74","author":"Duan","year":"2008","journal-title":"Appl. Environ. Microbiol."},{"issue":"5","key":"10.1016\/j.bcp.2024.116471_b0400","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.2337\/db14-0635","article-title":"Engineered commensal bacteria reprogram intestinal cells into glucose-responsive insulin-secreting cells for the treatment of diabetes","volume":"64","author":"Duan","year":"2015","journal-title":"Diabetes"},{"issue":"17","key":"10.1016\/j.bcp.2024.116471_b0405","doi-asserted-by":"crossref","first-page":"7565","DOI":"10.1007\/s00253-018-9155-6","article-title":"Engineered commensal bacteria prevent systemic inflammation-induced memory impairment and amyloidogenesis via producing GLP-1","volume":"102","author":"Chen","year":"2018","journal-title":"Appl. Microbiol. Biotechnol."},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0410","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/jnc.14694","article-title":"Neuroprotective effects of an engineered commensal bacterium in the 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine Parkinson disease mouse model via producing glucagon-like peptide-1","volume":"150","author":"Fang","year":"2019","journal-title":"J. Neurochem."},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0415","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s13568-020-01014-6","article-title":"Therapeutic effect of GLP-1 engineered strain on mice model of Alzheimer's disease and Parkinson's disease","volume":"10","author":"Fang","year":"2020","journal-title":"AMB Express"},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0420","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.synbio.2021.09.009","article-title":"Antidiabetic effect of an engineered bacterium Lactobacillus plantarum-pMG36e -GLP-1 in monkey model","volume":"6","author":"Luo","year":"2021","journal-title":"Synth. Syst. Biotechnol."},{"key":"10.1016\/j.bcp.2024.116471_b0425","article-title":"Engineered bacteria of MG1363-pMG36e-GLP-1 attenuated obesity-induced by high fat diet in mice","volume":"11","author":"Wang","year":"2021","journal-title":"Front. Cell. Infect. Microbiol."},{"issue":"7","key":"10.1016\/j.bcp.2024.116471_b0430","doi-asserted-by":"crossref","first-page":"3179","DOI":"10.1039\/D3FO00044C","article-title":"Improvement effect of a next-generation probiotic L. plantarum-pMG36e-GLP-1 on type 2 diabetes mellitus via the gut-pancreas-liver axis","volume":"14","author":"Hu","year":"2023","journal-title":"Food Funct."},{"issue":"5","key":"10.1016\/j.bcp.2024.116471_b0435","doi-asserted-by":"crossref","first-page":"e10351","DOI":"10.1002\/btm2.10351","article-title":"Neuroprotective effects of an engineered Escherichia coli Nissle 1917 on Parkinson's disease in mice by delivering GLP-1 and modulating gut microbiota","volume":"8","author":"Wu","year":"2023","journal-title":"Bioeng. Transl. Med."},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0440","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/1751-7915.14196","article-title":"Engineered probiotics Clostridium butyricum-pMTL007-GLP-1 improves blood pressure via producing GLP-1 and modulating gut microbiota in spontaneous hypertension rat models","volume":"16","author":"Wang","year":"2023","journal-title":"J. Microbial. Biotechnol."},{"issue":"8","key":"10.1016\/j.bcp.2024.116471_b0445","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.molmet.2016.06.006","article-title":"Microbially produced glucagon-like peptide 1 improves glucose tolerance in mice","volume":"5","author":"Arora","year":"2016","journal-title":"Mol Metab"},{"issue":"10","key":"10.1016\/j.bcp.2024.116471_b0450","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s10529-022-03288-1","article-title":"Oral glucagon-like peptide 1 analogue ameliorates glucose intolerance in db\/db mice","volume":"44","author":"Zhang","year":"2022","journal-title":"Biotechnol. Lett"},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0455","doi-asserted-by":"crossref","first-page":"6049","DOI":"10.1021\/acsnano.1c11536","article-title":"Light-sensitive lactococcus lactis for microbe-gut-brain axis regulating via upconversion optogenetic micro-nano system","volume":"16","author":"Pan","year":"2022","journal-title":"ACS Nano"},{"issue":"2","key":"10.1016\/j.bcp.2024.116471_b0460","doi-asserted-by":"crossref","first-page":"2829","DOI":"10.1007\/s12274-022-4963-5","article-title":"A micro-nano optogenetic system based on probiotics for in situ host metabolism regulation","volume":"16","author":"Zhang","year":"2023","journal-title":"Nano Res."},{"issue":"2","key":"10.1016\/j.bcp.2024.116471_b0465","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/oby.22700","article-title":"Genetically engineered escherichia coli nissle 1917 secreting GLP-1 analog exhibits potential antiobesity effect in high-fat diet-induced obesity mice","volume":"28","author":"Ma","year":"2020","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"10.1016\/j.bcp.2024.116471_b0470","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.1007\/s11095-014-1430-3","article-title":"Oral delivery of glucagon like peptide-1 by a recombinant Lactococcus lactis","volume":"31","author":"Agarwal","year":"2014","journal-title":"Pharm. Res."},{"issue":"9","key":"10.1016\/j.bcp.2024.116471_b0475","doi-asserted-by":"crossref","first-page":"e0162733","DOI":"10.1371\/journal.pone.0162733","article-title":"Oral delivery of pentameric glucagon-like peptide-1 by recombinant lactobacillus in diabetic rats","volume":"11","author":"Lin","year":"2016","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.bcp.2024.116471_b0480","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/S0026-0495(99)90043-4","article-title":"Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1","volume":"48","author":"Burcelin","year":"1999","journal-title":"Metabolism"},{"issue":"4","key":"10.1016\/j.bcp.2024.116471_b0485","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15041202","article-title":"The oral delivery system of modified GLP-1 by probiotics for T2DM","volume":"15","author":"Wang","year":"2023","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.bcp.2024.116471_b0490","doi-asserted-by":"crossref","first-page":"e0165130","DOI":"10.1371\/journal.pone.0165130","article-title":"Heterologous expression and delivery of biologically active exendin-4 by lactobacillus paracasei L14","volume":"11","author":"Zeng","year":"2016","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0495","doi-asserted-by":"crossref","DOI":"10.1007\/s12038-018-9831-9","article-title":"Construction of a dietary-cure Saccharomyces cerevisiae expressing long-acting glucagon-like peptide-1 and investigation of its hypoglycemic activity in type 2 diabetes mellitus mouse model","volume":"44","author":"Jiang","year":"2019","journal-title":"J. Biosci."},{"key":"10.1016\/j.bcp.2024.116471_b0500","doi-asserted-by":"crossref","DOI":"10.1016\/j.biomaterials.2023.122005","article-title":"A red light-controlled probiotic bio-system for in-situ gut-brain axis regulation","volume":"294","author":"Zhang","year":"2023","journal-title":"Biomaterials"},{"issue":"11","key":"10.1016\/j.bcp.2024.116471_b0505","doi-asserted-by":"crossref","first-page":"3433","DOI":"10.1021\/acssynbio.3c00455","article-title":"Cold exposure and oral delivery of GLP-1R agonists by an engineered probiotic yeast strain have antiobesity effects in mice","volume":"12","author":"Hedin","year":"2023","journal-title":"ACS Synth. Biol."},{"issue":"6","key":"10.1016\/j.bcp.2024.116471_b0510","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1016\/j.jhep.2021.12.003","article-title":"Promises of microbiome-based therapies","volume":"76","author":"Bajaj","year":"2022","journal-title":"J. Hepatol."},{"issue":"9","key":"10.1016\/j.bcp.2024.116471_b0515","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1038\/nbt.4222","article-title":"Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria","volume":"36","author":"Isabella","year":"2018","journal-title":"Nat. Biotechnol."},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0520","first-page":"94","article-title":"Plasmid vectors for in vivo selection-free use with the probiotic E","volume":"10","author":"Kan","year":"2021","journal-title":"Coli Nissle 1917, ACS Synth Biol"},{"issue":"11","key":"10.1016\/j.bcp.2024.116471_b0525","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1038\/s41574-020-0399-8","article-title":"Dipeptidyl peptidase 4 inhibitors in the treatment of type 2 diabetes mellitus","volume":"16","author":"Deacon","year":"2020","journal-title":"Nat. Rev. Endocrinol."},{"issue":"20","key":"10.1016\/j.bcp.2024.116471_b0530","doi-asserted-by":"crossref","first-page":"10706","DOI":"10.1039\/C6NR00294C","article-title":"In vivo dual-delivery of glucagon like peptide-1 (GLP-1) and dipeptidyl peptidase-4 (DPP4) inhibitor through composites prepared by microfluidics for diabetes therapy","volume":"8","author":"Araujo","year":"2016","journal-title":"Nanoscale"},{"issue":"2","key":"10.1016\/j.bcp.2024.116471_b0535","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1517\/13543776.2014.991309","article-title":"DPP-4 inhibitors: a patent review (2012\u20132014)","volume":"25","author":"Costante","year":"2015","journal-title":"Expert Opin. Ther. Pat."},{"issue":"2\u20133","key":"10.1016\/j.bcp.2024.116471_b0540","first-page":"61","article-title":"Enzymatic barriers for GI peptide and protein delivery","volume":"11","author":"Woodley","year":"1994","journal-title":"Crit. Rev. Ther. Drug Carrier Syst."},{"issue":"3","key":"10.1016\/j.bcp.2024.116471_b0545","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1021\/mp500809f","article-title":"Toward oral delivery of biopharmaceuticals: an assessment of the gastrointestinal stability of 17 peptide drugs","volume":"12","author":"Wang","year":"2015","journal-title":"Mol. Pharm."},{"issue":"7","key":"10.1016\/j.bcp.2024.116471_b0550","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.biotechadv.2014.07.006","article-title":"A review of advanced oral drug delivery technologies facilitating the protection and absorption of protein and peptide molecules","volume":"32","author":"Choonara","year":"2014","journal-title":"Biotechnol. Adv."},{"issue":"3","key":"10.1016\/j.bcp.2024.116471_b0555","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.ejpb.2013.12.017","article-title":"The role of citric acid in oral peptide and protein formulations: relationship between calcium chelation and proteolysis inhibition","volume":"86","author":"Welling","year":"2014","journal-title":"Eur. J. Pharm. Biopharm."},{"issue":"10","key":"10.1016\/j.bcp.2024.116471_b0560","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1007\/s00125-023-05929-0","article-title":"Gut hormone-based pharmacology: novel formulations and future possibilities for metabolic disease therapy","volume":"66","author":"Tschop","year":"2023","journal-title":"Diabetologia"},{"issue":"17","key":"10.1016\/j.bcp.2024.116471_b0565","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2174\/1389557520666200628032507","article-title":"The research progress of DPP-4 inhibitors","volume":"20","author":"Sun","year":"2020","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.bcp.2024.116471_b0570","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2020.08.003","article-title":"Small-molecule GLP-1 secretagogs: challenges and recent advances","author":"He","year":"2020","journal-title":"Drug Discov. Today"},{"issue":"12","key":"10.1016\/j.bcp.2024.116471_b0575","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126623","article-title":"Improvement of glucose tolerance by food factors having glucagon-like peptide-1 releasing activity","volume":"22","author":"Hira","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"19","key":"10.1016\/j.bcp.2024.116471_b0580","doi-asserted-by":"crossref","first-page":"4738","DOI":"10.1111\/bph.15896","article-title":"Novel luciferase-based glucagon-like peptide 1 reporter assay reveals naturally occurring secretagogues","volume":"179","author":"Anghel","year":"2022","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.bcp.2024.116471_b0585","doi-asserted-by":"crossref","DOI":"10.2337\/db23-0553","article-title":"Gut microbiota-tryptophan metabolism-GLP-1 axis participates in beta-cell regeneration induced by dapagliflozin","author":"Jiang","year":"2024","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/j.bcp.2024.116471_b0590","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.ymthe.2016.11.008","article-title":"A synthetic-biology-inspired therapeutic strategy for targeting and treating hepatogenous diabetes","volume":"25","author":"Xue","year":"2017","journal-title":"Mol. Ther."},{"issue":"6037","key":"10.1016\/j.bcp.2024.116471_b0595","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203535","article-title":"A synthetic optogenetic transcription device enhances blood-glucose homeostasis in mice","volume":"332","author":"Ye","year":"2011","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0600","doi-asserted-by":"crossref","first-page":"2318","DOI":"10.1038\/s41467-018-04744-1","article-title":"Caffeine-inducible gene switches controlling experimental diabetes","volume":"9","author":"Bojar","year":"2018","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116471_b0605","article-title":"Bile acid signaling in the regulation of whole body metabolic and immunological homeostasis, Sci China","author":"Jia","year":"2023","journal-title":"Life Sci."},{"key":"10.1016\/j.bcp.2024.116471_b0610","doi-asserted-by":"crossref","DOI":"10.1074\/jbc.RA120.016203","article-title":"Muscle-specific TGR5 overexpression improves glucose clearance in glucose-intolerant mice","volume":"296","author":"Sasaki","year":"2021","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0615","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/s41467-021-21744-w","article-title":"Hyocholic acid species as novel biomarkers for metabolic disorders","volume":"12","author":"Zheng","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2024.116471_b0620","doi-asserted-by":"crossref","unstructured":"J. She, G. Tuerhongjiang, M. Guo, J. Liu, X. Hao, L. Guo, N. Liu, W. Xi, T. Zheng, B. Du, B. Lou, X. Gao, X. Yuan, Y. Yu, Y. Zhang, F. Gao, X. Zhuo, Y. Xiong, X. Zhang, J. Yu, Z. Yuan, Y. Wu, Statins aggravate insulin resistance through reduced blood glucagon-like peptide-1 levels in a microbiota-dependent manner, Cell Metab 36(2) (2024) 408-421 e5.","DOI":"10.1016\/j.cmet.2023.12.027"},{"issue":"12","key":"10.1016\/j.bcp.2024.116471_b0625","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1517\/14712598.2010.532786","article-title":"Treatment of diabetes with glucagon-like peptide-1 gene therapy","volume":"10","author":"Riedel","year":"2010","journal-title":"Expert Opin. Biol. Ther."},{"issue":"9","key":"10.1016\/j.bcp.2024.116471_b0630","doi-asserted-by":"crossref","first-page":"5266","DOI":"10.1038\/s41380-021-01043-y","article-title":"Reducing alcohol and\/or cocaine-induced reward and toxicity via an epidermal stem cell-based gene delivery platform","volume":"26","author":"Kong","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.bcp.2024.116471_b0635","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jconrel.2017.08.035","article-title":"Oral delivery of a therapeutic gene encoding glucagon-like peptide 1 to treat high fat diet-induced diabetes","volume":"268","author":"Nurunnabi","year":"2017","journal-title":"J. Control. Release"},{"issue":"11","key":"10.1016\/j.bcp.2024.116471_b0640","doi-asserted-by":"crossref","first-page":"4666","DOI":"10.1021\/acs.nanolett.1c00832","article-title":"Plasmid DNA nanoparticles for nonviral oral gene therapy","volume":"21","author":"Shahriar","year":"2021","journal-title":"Nano Lett."},{"issue":"35","key":"10.1016\/j.bcp.2024.116471_b0645","doi-asserted-by":"crossref","first-page":"38925","DOI":"10.1021\/acsami.0c09814","article-title":"Oral GLP1 gene delivery by an antibody-guided nanomaterial to treat type 2 diabetes mellitus","volume":"12","author":"Hasan","year":"2020","journal-title":"ACS Appl. Mater. Interfaces"},{"issue":"3","key":"10.1016\/j.bcp.2024.116471_b0650","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1021\/acsnanoscienceau.3c00035","article-title":"Enhancing the therapeutic efficacy of GLP-1 for hyperglycemia treatment: overcoming barriers of oral gene therapy with taurocholic acid-conjugated protamine sulfate and calcium phosphate","volume":"4","author":"Shahriar","year":"2024","journal-title":"ACS Nanosci Au"},{"key":"10.1016\/j.bcp.2024.116471_b0655","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.addr.2016.01.010","article-title":"Oral delivery of macromolecular drugs: where we are after almost 100years of attempts","volume":"101","author":"Moroz","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.bcp.2024.116471_b0660","doi-asserted-by":"crossref","DOI":"10.1177\/1179551420984130","article-title":"Oral GLP1 analog: where does the tide go?","volume":"13","author":"Gardner","year":"2020","journal-title":"Clin. Med. Insights Endocrinol. Diabetes"},{"issue":"1","key":"10.1016\/j.bcp.2024.116471_b0665","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3803\/EnM.2021.102","article-title":"Peptidyl and non-peptidyl oral glucagon-like peptide-1 receptor agonists","volume":"36","author":"Choe","year":"2021","journal-title":"Endocrinol. Metab. (Seoul)"},{"issue":"467","key":"10.1016\/j.bcp.2024.116471_b0670","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aar7047","article-title":"Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist","volume":"10","author":"Buckley","year":"2018","journal-title":"Sci. Transl. Med."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224004544?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295224004544?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T13:15:51Z","timestamp":1741698951000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295224004544"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":134,"alternative-id":["S0006295224004544"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116471","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peptide GLP-1 receptor agonists: From injection to oral delivery strategies","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2024.116471","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116471"}}